Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.
SciSparc Ltd. (Nasdaq: SPRC) generates news across clinical-stage pharmaceuticals, intellectual property, medical devices, and advanced computing initiatives. Through its majority-owned subsidiary NeuroThera Labs Inc., the company reports progress on cannabinoid-based drug candidates, patent grants, and collaborations targeting central nervous system and neuropsychiatric disorders.
Investors following SPRC news can expect updates on drug development programs such as SCI-110, for Tourette syndrome and for the treatment of Alzheimer’s disease and agitation, and SCI-210, for autism spectrum disorder (ASD) and status epilepticus. Company announcements also cover patent activity, including NeuroThera’s opioid–N-acylethanolamine platform for pain management and MEAI-based combination therapies for depression and addiction-related indications.
SciSparc’s news flow extends to corporate transactions and strategic repositioning. Recent disclosures include the transfer of its advanced clinical-stage pharmaceutical portfolio and its stake in SciSparc Nutraceuticals Inc. into NeuroThera Labs Inc., the sale of oncology-focused subsidiary MitoCareX Bio Ltd. to N2OFF, Inc., and a binding term sheet followed by a definitive agreement to acquire a treasury of patents and trademarks for innovative endoscopic systems and medical cameras, including the MUSE system for GERD treatment.
Another recurring theme in SPRC news is technology-driven R&D. The company has announced a quantum computing-enabled 3D protein modeling initiative aimed at improving drug discovery, as well as a non-binding term sheet for NeuroThera to acquire a majority stake in a quantum bio data analysis company. Regulatory and capital markets items, such as Nasdaq compliance notifications, warrant inducement agreements, and SEC Form 6-K filings, also appear in its news stream. For a structured view of these developments, the SciSparc news page aggregates press releases and related coverage in one place.
SciSparc (Nasdaq: SPRC) announced on Feb 2, 2026 that NeuroThera Labs was granted a U.S. patent for a proprietary combination of antimicrobials and cannabinoids designed to potentiate antibiotics versus resistant Gram-positive pathogens such as MRSA.
The patent joins prior U.S. and European grants, is based on preclinical data, and targets a global antibiotics market projected near $58 billion in 2026. SciSparc holds an approximate 75% controlling interest in NeuroThera.
SciSparc (Nasdaq: SPRC) closed the acquisition of an intellectual property portfolio from Xylo Technologies on January 26, 2026, acquiring patents, trademarks and know‑how centered on the single‑use MUSE™ endoscopic system for transoral fundoplication to treat GERD.
Consideration included ordinary shares representing 19.99% of SciSparc and pre‑funded warrants in lieu of some shares. SciSparc intends to commence immediate commercialization and pursue exclusive regional distributor partnerships in North America, Europe and Latin America. The release notes Xylo previously received $3.0M up front in 2019 under a Greater China licensing deal and cites a MarkNtel market estimate valuing the global GERD device market at $2.5B (2024), projected to $3.03B by 2030 (CAGR 3.24% 2025–2030).
SciSparc (Nasdaq: SPRC) signed a definitive agreement to acquire a portfolio of patents, trademarks and know‑how for endoscopic systems and medical cameras, chiefly the MUSE™ single‑use transoral fundoplication device. The Closing is set for March 8, 2026, at which SciSparc will issue ordinary shares that will represent 19.99% of issued and outstanding share capital to Xylo (or pre‑funded warrants in lieu).
SciSparc plans immediate commercialization after closing, aims to replicate Xylo’s 2019 Greater China licensing model (which generated a $3.0M up‑front payment), and cites a GERD device market roughly <$b>$2.5B in 2024, projected to $3.03B by 2030.
SciSparc (Nasdaq: SPRC) received a Nasdaq notification that it is not in compliance with the minimum stockholders’ equity requirement under Rule 5550(b)(1), which requires at least $2,500,000 in equity. The company reported approximately $(81,000) in stockholders’ equity as of June 30, 2025. SciSparc has 45 calendar days (until February 26, 2026) to submit a plan to regain compliance; if accepted Nasdaq may grant up to a 180-day extension to evidence compliance. The notice has no immediate effect on listing and shares will continue trading as SPRC. The company expects to demonstrate compliance as of December 31, 2025 following proceeds from an $4.2 million debenture conversion in August 2025 and its November 2025 registered direct offering.
SciSparc (Nasdaq: SPRC) said NeuroThera Labs received an Israel patent for a proprietary combination of opioids and N-acylethanolamines designed to potentiate analgesia while reducing side effects.
The grant complements existing patents in Europe, Japan, Australia, and Canada. SciSparc holds a controlling interest of approximately 75% in NeuroThera. A pre-clinical study reported that combining palmitoylethanolamide (PEA) with oxycodone prolonged analgesic effect and reduced some oxycodone-related psychoactive adverse events. The release cites a $5.5–$5.7 billion 2024 global oxycodone market estimate and suggests an "opioid-sparing" effect that may lower required opioid doses.
SciSparc (Nasdaq: SPRC) announced on Dec. 2, 2025 that NeuroThera Labs (TSXV: NTLX), in which SciSparc holds a controlling interest of approximately 75%, signed a non-binding term sheet to acquire a majority stake in an Israeli quantum-enabled bio data analytics company.
Under the Term Sheet NeuroThera would acquire 55% equity of the Target Company in exchange for issuing common shares equal to 40% of NeuroThera’s share capital on a non-diluted basis. The Acquisition is subject to due diligence, definitive agreements, corporate and regulatory approvals, and customary closing conditions; there is no assurance the transaction will be completed.
SciSparc (Nasdaq: SPRC) signed a binding term sheet to acquire a treasury of patents, trademarks and IP rights for endoscopic systems and medical cameras from Xylo Technologies, principally the single-use MUSE™ transoral fundoplication system.
The consideration at closing will be ordinary shares representing 19.99% of SciSparc’s issued and outstanding share capital (or, at SciSparc’s option, pre-funded warrants). SciSparc plans to pursue exclusive distributor partnerships to commercialize MUSE across North America, Europe and Latin America. A May 2025 report valued the global GERD device market at $2.5B (2024), projected to $3.03B by 2030 (CAGR 3.24% 2025–2030).
SciSparc (Nasdaq: SPRC) signed a binding term sheet to acquire a treasury of patents, trademarks and know‑how for innovative endoscopic systems and medical cameras, principally the MUSE™ transoral fundoplication system from Xylo Technologies.
Under the term sheet SciSparc will issue upon closing ordinary shares representing 19.99% of issued and outstanding capital (or pre‑funded warrants in lieu). SciSparc plans to pursue exclusive regional distributor partnerships to commercialize MUSE™ across North America, Europe and Latin America. A May 2025 market report values the global GERD device market at $2.5B in 2024, projected to $3.03B by 2030 (CAGR 3.24% 2025–2030).
SciSparc (Nasdaq: SPRC) said on November 20, 2025 that NeuroThera Labs (TSXV: NTLX), in which SciSparc holds approximately 75% controlling interest, filed an Israeli patent application for a combination therapy of MEAI (5-methoxy-2-aminoindane) and N-acylethanolamines such as PEA targeting depression.
The filing expands a joint IP portfolio with Clearmind Medicine (Nasdaq: CMND); the collaboration has produced 13 patents filed to date covering MEAI and N-acylethanolamine combinations for disorders including alcohol use disorder, cocaine addiction, obesity and depression. The release cites preclinical data supporting MEAI's efficacy in reducing addictive behaviors while preserving normal reward pathways.
The announcement references World Health Organization data (August 2025) noting ~332 million people living with depression worldwide (≈5.7% of adults).
SciSparc (Nasdaq: SPRC) closed the acquisition and transfer transaction with Miza III Ventures (now Neurothera Labs Inc., TSXV: NTLX) effective October 22, 2025. SciSparc received 63,300,000 common shares, 4,000,000 warrants exercisable at CAD 0.25 until October 22, 2030, and up to 48,000,000 contingent rights tied to milestones. The Target Assets transferred had an aggregate value of approximately US$11.6 million while Neurothera enterprise value was ~US$3.3 million (including ~US$1.0M cash).
SciSparc holds a controlling stake of ~75%, potentially rising to ~84% if warrants and milestones are fully executed. SciSparc also committed CAD 1.0M via an unsecured convertible note maturing October 22, 2027. Transaction Securities are subject to TSXV escrow and final TSXV acceptance is pending.
FAQ
What is the current stock price of Scisparc (SPRC)?
What is the market cap of Scisparc (SPRC)?
